# US 2026/0086099 A1 · Biomarker for myasthenia gravis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0086099 A1
- Document ID: US20260086099A1
- Status: Published application
- Kind: A1
- Application number: 19/111,505
- Filed: 2023-09-11
- Published: 2026-03-26
- Earliest claimed: 2022-09-13
- Assignees: Heinrich-Heine-Universitaet Duesseldorf
- Applicants: Heinrich-Heine-Universitaet Duesseldorf
- Inventors: Sven Guenther MEUTH; Tobias RUCK; Christopher Jannik NELKE; Christina Barbara SCHROETER
- Web page: https://patentgrep.com/patent/US20260086099A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/28: Neurological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for determining disease activity of myasthenia gravis in a patient, comprising determining the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) level in an in vitro sample from the patient. Furthermore, the invention relates to a kit for use in such method comprising means for determining the ITIH3 level in a sample and instructions for carrying out the method.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for determining disease activity of myasthenia gravis in a patient, comprising determining the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) level in an in vitro sample from the patient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sample comprises or consists of a body fluid or fraction thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the body fluid is selected from the group consisting of blood, a blood fraction, lymph, a lymph fraction, a liquor, a liquor fraction, an interstitial fluid, an interstitial fluid fraction, a transcellular fluid, a transcellular fluid fraction, urine, and a urine fraction.

### Claim 19 (depends on 16)

The method of claim 16, wherein the sample comprises or consists of a serum sample or fraction thereof.

### Claim 20 (depends on 16)

The method of claim 16, wherein the patient is known or suspected to suffer from myasthenia gravis.

### Claim 21 (depends on 16)

The method of claim 16, wherein the patient:
has or had a thymoma and/or thymic lymphofollicular hyperplasia; and/or
is or has been subjected to immuno-suppression, immune modulation, inhibition of acetylcholine esterase, partial or complete removal of autoantibodies, or a combination of two or more thereof.

### Claim 22 (depends on 16)

The method of claim 16, wherein the patient has increased levels of at least one autoantibody as compared to the level of the at least one autoantibody in an average healthy subject, wherein the at least one or more increased autoantibody levels are autoantibodies specific for acetylcholine receptors, autoantibodies specific low-density lipoprotein receptor-related protein 4 (LRP4), and/or autoantibodies specific muscle specific tyrosine kinase (MuSK).

### Claim 23 (depends on 16)

The method of claim 16, wherein the step of determining the ITIH3 level comprises determining the level of ITIH3 polypeptide.

### Claim 24 (depends on 23)

The method of claim 23, wherein the level of ITIH3 polypeptide is determined by one of the following assays or a combination of two or more of the following assays: enzyme-linked immunosorbent assay (ELISA), mass spectrometry, immuno-electrophoresis, immunofluorescence, flow cytometry, immuno-blotting, Western blot, SDS-PAGE, capillary electrophoresis (CE), and chemiluminescence.

### Claim 25 (depends on 16)

The method of claim 16, wherein the sample comprises a tissue sample, and/or wherein the step of determining the ITIH3 level comprises determining the level of ITIH3 mRNA in the sample.

### Claim 26 (depends on 25)

The method of claim 25, wherein the tissue sample comprises a muscle tissue sample.

### Claim 27 (depends on 25)

The method of claim 25, wherein determining the level of ITIH3 mRNA is performed by conducting at least one step selected from the group consisting of polymerase chain reaction (PCR), in situ hybridization, gel electrophoresis, Northern Blot, Southern Blot, immunofluorescence, and combinations of two or more thereof.

### Claim 28 (depends on 16)

The method of claim 16, wherein determining disease activity of myasthenia gravis comprises determining severity and/or prognosis of progress of myasthenia gravis.

### Claim 29 (depends on 28)

The method of claim 28, wherein determining severity and/or prognosis of progress of myasthenia gravis is determined as progress of myasthenia gravis in 12 months, and/or wherein disease activity of myasthenia gravis is categorized into:
(a) mild myasthenia gravis according to Myasthenia Gravis Foundation of America clinical classification (MGFA) class I or II;
(b) moderate myasthenia gravis according to MGFA class III; and
(c) severe myasthenia gravis according to MGFA class IV or V,
wherein the ITIH3 level indicates severity of myasthenia gravis.

### Claim 30 (depends on 16)

The method of claim 16, wherein determining disease activity of myasthenia gravis comprises or consists of determining severity and/or prognosis of progress of myasthenia gravis, corresponding with at least one established method for determining severity of myasthenia gravis, selected from Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities Daily Living (MG-ADL) score.

### Claim 31 (depends on 16)

The method of claim 16, further comprising comparing the determined ITIH3 level with:
(a) a predetermined reference value R1 indicating the borderline between a sample indicating a disease activity of myasthenia gravis of interest and a sample indicating the absence of said disease activity; and/or
(b) an ITIH3 level determined in a control sample C obtained from a control patient of the same species not having the disease activity of myasthenia gravis of interest.

### Claim 32 (depends on 31)

The method of claim 31, wherein myasthenia gravis is categorized in that
(I) an ITIH3 level determined in the sample that is higher than R1 and/or at least 20% higher than the ITIH3 level of control sample C indicates the disease activity of myasthenia gravis of interest in the patient; and/or
(II) an ITIH3 level determined in the sample that is lower than R1 and/or less than 20% higher than the ITIH3 level of control sample C indicates that the patient is not having the disease activity of myasthenia gravis of interest,
wherein the ITIH3 level in each case is related to the total polypeptide content comprised in the respective sample.

### Claim 33 (depends on 16)

The method of claim 16, wherein an increase in ITIH3 level is associated with an upregulation of complement system and/or platelet activation.

### Claim 34 (depends on 16)

A kit for use in a method according to claim 16, comprising:
(A) reagents for determining the ITIH3 level in a sample; and
(B) instructions for carrying out the method of claim 16.

### Claim 35

Use of ITIH3 as a biomarker for determining disease activity of myasthenia gravis in a patient.
